Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Share-based Compensation (2020 - 2025)

Historic Share-based Compensation for Gain Therapeutics (GANX) over the last 6 years, with Q3 2025 value amounting to $460005.0.

  • Gain Therapeutics' Share-based Compensation rose 2867.09% to $460005.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 million, marking a year-over-year decrease of 3190.51%. This contributed to the annual value of $2.4 million for FY2024, which is 2666.03% down from last year.
  • As of Q3 2025, Gain Therapeutics' Share-based Compensation stood at $460005.0, which was up 2867.09% from $522019.0 recorded in Q2 2025.
  • In the past 5 years, Gain Therapeutics' Share-based Compensation registered a high of $1.5 million during Q2 2024, and its lowest value of $110725.0 during Q1 2021.
  • Over the past 5 years, Gain Therapeutics' median Share-based Compensation value was $359329.0 (recorded in 2024), while the average stood at $489713.1.
  • Its Share-based Compensation has fluctuated over the past 5 years, first surged by 33347.8% in 2023, then crashed by 6632.24% in 2024.
  • Quarter analysis of 5 years shows Gain Therapeutics' Share-based Compensation stood at $172333.0 in 2021, then soared by 224.19% to $558692.0 in 2022, then decreased by 0.65% to $555059.0 in 2023, then tumbled by 35.26% to $359329.0 in 2024, then rose by 28.02% to $460005.0 in 2025.
  • Its last three reported values are $460005.0 in Q3 2025, $522019.0 for Q2 2025, and $419504.0 during Q1 2025.